We demonstrated that the tumor suppressive is mediated by both positively and negatively acting downstream effectors, including CBX6, TRIB3, ETV4 and FOS/JUN, where the first two also affect the differentiation status of Lp30 AML. This evidence concerns the gene FOS and acute myeloid leukemia.